RxDoctor Payments Data

Melissa Steele, APRN

Family · Dover, TNNPI 1619344231

Payments from drug & device makers

$554in general payments, 2019–2025

Across 32 payments — averaging $17.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$126
  • Novartis$100
  • AstraZeneca$73
  • Novo Nordisk$59
  • Medtronic$54
  • Dexcom, Inc.$47
  • plus $96 from 5 others

What the payments were for

  • Food & beverage$554100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$554 in reported general payments places this provider in the 50th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$1,401
Medicare patients
35
Services billed
140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide65$79,800
TrulicityDulaglutide31$55,448
MounjaroTirzepatide34$41,060
JardianceEmpagliflozin42$38,035
JanuviaSitagliptin Phosphate40$37,332
UbrelvyUbrogepant14$32,572
FarxigaDapagliflozin Propanediol46$32,478
RexultiBrexpiprazole12$28,732
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$27,168
RybelsusSemaglutide23$26,817
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,313
XareltoRivaroxaban11$9,127
Aimovig AutoinjectorErenumab-Aooe12$8,879
Lantus SolostarInsulin Glargine,hum.Rec.Anlog67$8,866
SymbicortBudesonide/Formoterol Fumarate26$6,602

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$59$106,61788 claims
Lilly USA, LLCTrulicity, Mounjaro$33$96,50865 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$73$48,39387 claims
AbbVieUbrelvy, Synthroid$126$33,95642 claims
Otsuka America Pharmaceutical, Inc.Rexulti$17$28,73212 claims
GSKTrelegy Ellipta$17$27,16838 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 6,706 family providers in Tennessee.

Other family in Dover

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →